Metformin Use Guidelines

Introduction to Metformin Contraindications

The American Journal of Kidney Diseases recommends using glipizide or gliclazide, second-generation sulfonylureas without active metabolites, in patients with chronic kidney disease (CKD) 1
The American Journal of Kidney Diseases suggests repaglinide, a meglitinide, as a suitable alternative because it does not produce increased active metabolites with decreased kidney function, unlike nateglinide 1
The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines from 2007 used serum creatinine cutoffs, but current guidance prioritizes eGFR-based thresholds for assessing renal clearance 1

Insulin therapy is recommended as the safest approach during acute metabolic derangements by Praxis Medical Insights 2
DPP-4 inhibitors may be safer alternatives in patients with a history of metabolic issues who have recovered and need oral therapy, according to Praxis Medical Insights 2

Active alcohol abuse or chronic alcoholism is a contraindication for metformin use, as alcohol potentiates metformin's effect on lactate metabolism and impairs lactate clearance, according to Praxis Medical Insights 3
Acute congestive heart failure with hypoperfusion/hypoxemia is a contraindication due to tissue hypoxia impairing lactate clearance, as stated by Praxis Medical Insights 3
Metabolic encephalopathy or conditions causing metabolic derangements are contraindications because metformin accumulation creates a dangerous cycle where metabolic derangements further impair drug clearance, according to Praxis Medical Insights 2
Acute illness causing dehydration, hypoxemia, or sepsis requires immediate metformin discontinuation, as stated by Praxis Medical Insights 3

The risk of metformin-associated lactic acidosis (MALA) is concentration-dependent and requires both elevated metformin levels plus a secondary precipitating event, although the overall incidence is low in appropriately selected patients 1
Key warning signs of MALA include malaise, myalgias, abdominal pain, respiratory distress, increased somnolence, hypotension, and resistant bradyarrhythmias, with laboratory findings showing elevated blood lactate, anion gap acidosis without ketonuria, and increased lactate:pyruvate ratio 1

Metformin as monotherapy is not associated with hypoglycemia, as its primary mechanism decreases hepatic glucose output and improves peripheral insulin sensitivity without stimulating insulin secretion, making it safe for use in prediabetic patients, according to the American Diabetes Association 4
Multiple guidelines, including those from the American College of Clinical Endocrinologists, consistently emphasize that metformin monotherapy does not produce hypoglycemia under normal circumstances, with a strength of evidence rated as high 4, 5

In patients with impaired renal function, the primary concern is lactic acidosis, not hypoglycemia, as metformin accumulation can occur, and the kidney's ability to clear insulin and contribute to gluconeogenesis is impaired, as noted by the National Kidney Foundation 6
The kidney normally clears approximately one-third of circulating insulin, and impaired renal function can lead to increased hypoglycemia risk from insulin or sulfonylurea therapy, not metformin itself, according to the American Journal of Kidney Diseases 6

Sulfonylureas cause prolonged, life-threatening hypoglycemia, particularly in elderly patients and those with renal impairment, and should be avoided in patients with chronic kidney disease, as recommended by the American Geriatrics Society 4, 6
First-generation sulfonylureas should be completely avoided in patients with chronic kidney disease due to active metabolites that accumulate, while second-generation agents like glipizide and gliclazide are preferred, according to the National Institute of Diabetes and Digestive and Kidney Diseases 6

DPP-4 inhibitors may be safer alternatives to sulfonylureas once the patient stabilizes, as they do not cause hypoglycemia when used alone, with a strength of evidence rated as moderate, as noted by the European Association for the Study of Diabetes 7
Alpha-glucosidase inhibitors have very low hypoglycemia risk when used alone, making them a potential option for patients with impaired renal function, according to the American College of Clinical Endocrinologists 7